Pharma

Pfizer Inc. Successfully Completed Acquisition of the Therachon

Pfizer Inc. introduced the successful completion of its acquisition of the privately-held clinical-stage biotechnology firm Therachon Holding AG. Under the terms of the deal, Pfizer acquired Therachon for $340 million with an extra $470 million in additional payments unforeseen on the achievement of critical milestones within the improvement and commercialization of TA-46. TA-46 is an investigational medicine for the treatment of achondroplasia – a genetic condition, and the most typical type of short-limb dwarfism. There are presently no approved therapy options for achondroplasia.

Therachon becoming a part of Pfizer is representative of our Rare Disease team’s 30-year dedication to developing modern medicines that address significant unmet medical needs of individuals with rare diseases, stated Seng Cheng, Senior Vice President and Chief Scientific Officer at Pfizer’s Rare Disease Research Unit. “With our main scientific and development capabilities, we imagine we will successfully advance the event of TA-46, which has the potential to be a first-in-class remedy for the treatment of achondroplasia.”

The transaction is just not anticipated to affect Pfizer’s present 2019 adjusted financial guidance.

At Pfizer, we apply science and our world assets to convey therapies to individuals that extend and considerably improve their lives. We attempt to set the usual for quality, security, and worth within the discovery, improvement, and manufacture of health care products. Our world portfolio contains medicines and vaccines, in addition to most of the world’s best-known client health care merchandise. Each day, Pfizer colleagues work throughout developed and rising markets to advance wellness, prevention, therapies and cures that problem primarily the most feared diseases of our time. In keeping with our duty as one of many world’s premier innovative biopharmaceutical corporations, we collaborate with health care suppliers, governments and local communities to help and increase entry to dependable, inexpensive health care all over the world. For greater than 150 years, we have now labored to make a difference for all who depend on us.

Tags

Nicholas Shorts

Nicholas leads the Pharma column. He is an excellent writer and a team leader with five years’ experience in medical writing. Nicholas is a Journalism degree holder from Texas A&M University. Before taking up Medical literature, he was a Journalism professor. Nicholas is also a poet.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Close
Close